What is OmniAb?
Founded in 2007, OmniAb operates at the intersection of advanced biological engineering and computational drug discovery. The company provides a comprehensive ecosystem of transgenic animal models—including OmniRat, OmniMouse, and OmniChicken—which are engineered to produce human-sequence antibodies. This biological capability is augmented by the OmniDeep platform, an in silico suite designed to optimize therapeutic candidates. By integrating high-throughput screening with specialized immunization methods, OmniAb enables its partners to develop complex modalities such as bispecific antibodies and antibody-drug conjugates with greater efficiency and precision. The firm serves as a vital infrastructure provider for the pharmaceutical industry, streamlining the transition from target identification to clinical candidate selection.
How much funding has OmniAb raised?
OmniAb has raised a total of $30M across 1 funding round:
Private Equity
$30M
Private Equity (2025): $30M, investors not publicly disclosed
Key Investors in OmniAb
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for OmniAb?
With the successful completion of this major enterprise-level funding, OmniAb is well-positioned to scale its R&D operations and expand the reach of its proprietary discovery platforms. The strategic allocation of this capital will likely focus on enhancing the computational capabilities of the OmniDeep suite and broadening the utility of its transgenic animal technologies. As the demand for novel therapeutic modalities grows, OmniAb is expected to leverage this financial backing to deepen its integration within the global drug development pipeline, potentially exploring new frontiers in antibody-drug conjugate design and bispecific antibody engineering. The company remains a key enabler for pharmaceutical innovation, with a clear trajectory toward sustained growth in the competitive biotech landscape.
See full OmniAb company page
